NewsPronto

 
Times Advertising


.

ACN Newswire

Read more press releases from ACN Newswire here

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

  • Written by ACN Newswire

image

TOKYO, Dec 24, 2019 - (JCN Newswire) - Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan, pending regulatory...

Read more: Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational...